United Therapeutics Appoints Dr. Kevin J. Tracey to Board

By Chris Stiles • Friday, January 23 03:33 • Permanent Link

United Therapeutics Corporation (NASDAQ: UTHR) has announced the appointment of Dr. Kevin J. Tracey to its board of directors. Dr. Tracey, who brings a wealth of scientific leadership and entrepreneurial experience, was appointed on January 21, 2026. He is the President, CEO, and the Karches Family Distinguished Chair in Medical Research at the Feinstein Institutes for Medical Research, and also holds several other prestigious positions in the field of medicine and research.

Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, expressed excitement about Dr. Tracey's appointment, stating that his strategic vision and scientific expertise will provide invaluable guidance to the company's mission and growth.

Dr. Tracey himself expressed enthusiasm to support United Therapeutics in its patient-driven mission to transform the treatment of rare diseases and expand the availability of transplantable organs.

Christopher Causey, Chairperson of the Nominating and Governance Committee of United Therapeutics’ board of directors, highlighted Dr. Tracey's invaluable scientific insight and operational healthcare experience as a significant addition to the board.

United Therapeutics is known for its commitment to innovation for unmet medical needs, particularly in the field of rare pulmonary diseases and organ manufacturing development programs. As a public benefit corporation (PBC), the company's public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

The addition of Dr. Tracey to the board reflects the company's commitment to strong board refreshment, bringing in individuals with valuable expertise and experience to drive the company's mission forward. Today the company's shares have moved -1.5% to a price of $464.93. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.